Jazz Pharmaceuticals shared its Q3 results, showing record sales of $1.24 billion, up 10% from last year.

JAZZ · Jazz Pharmaceuticals

The AI's read

Growth comes from several medicines, not just one: oncology sales rose 35%, and Xywav sales rose 12%. Zihera’s launch has also drawn early interest. Jazz says Epidiolex performed solidly despite outside challenges. The call gives no size for those challenges. Strong sales across products and the higher company forecast point to a stronger business outlook. Early trial results and possible future sales remain uncertain.